Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma

NCT06968988 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Soft-tissue Sarcoma

Interventions

DRUG: Zanzalintinib
DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Washington University School of Medicine

Collaborators

[object Object]